Perrigo Company plc $PRGO Shares Sold by Seven Six Capital Management LLC

Seven Six Capital Management LLC cut its position in shares of Perrigo Company plc (NYSE:PRGO) by 25.1% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 286,300 shares of the company’s stock after selling 96,100 shares during the quarter. Perrigo accounts for approximately 3.2% of Seven Six Capital Management LLC’s holdings, making the stock its 16th largest position. Seven Six Capital Management LLC’s holdings in Perrigo were worth $3,075,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its holdings in Perrigo by 3.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock valued at $244,634,000 after acquiring an additional 653,925 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Perrigo by 7.9% in the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after purchasing an additional 1,101,154 shares during the period. Fuller & Thaler Asset Management Inc. increased its stake in Perrigo by 291.9% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after purchasing an additional 5,828,076 shares during the last quarter. State Street Corp lifted its position in Perrigo by 9.5% during the second quarter. State Street Corp now owns 7,340,323 shares of the company’s stock worth $196,134,000 after buying an additional 637,678 shares during the period. Finally, Thompson Siegel & Walmsley LLC boosted its stake in Perrigo by 28.4% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock worth $64,848,000 after buying an additional 1,029,770 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Analyst Upgrades and Downgrades

PRGO has been the topic of a number of recent analyst reports. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $19.33.

Perrigo Stock Performance

NYSE:PRGO opened at $10.45 on Thursday. The firm has a 50-day moving average of $10.57 and a two-hundred day moving average of $11.68. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The stock has a market cap of $1.45 billion, a P/E ratio of -0.80, a PEG ratio of 1.22 and a beta of 0.51. Perrigo Company plc has a 1-year low of $9.23 and a 1-year high of $28.22.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the company posted $0.60 EPS. Perrigo’s quarterly revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, research analysts expect that Perrigo Company plc will post 2.11 earnings per share for the current fiscal year.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.